Amgen Inc. (NASDAQ:AMGN) Holdings Lifted by Trillium Asset Management LLC

Trillium Asset Management LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 911 shares of the medical research company’s stock after buying an additional 37 shares during the period. Trillium Asset Management LLC’s holdings in Amgen were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Generali Asset Management SPA SGR bought a new stake in Amgen during the 4th quarter valued at $15,858,000. Horizon Investments LLC raised its stake in shares of Amgen by 1.9% during the fourth quarter. Horizon Investments LLC now owns 14,820 shares of the medical research company’s stock valued at $3,863,000 after purchasing an additional 281 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in Amgen by 1.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 494,082 shares of the medical research company’s stock worth $129,129,000 after purchasing an additional 4,997 shares during the period. Kensington Investment Counsel LLC grew its position in Amgen by 4.5% in the 4th quarter. Kensington Investment Counsel LLC now owns 15,050 shares of the medical research company’s stock valued at $3,923,000 after buying an additional 651 shares in the last quarter. Finally, Mystic Asset Management Inc. increased its stake in Amgen by 75.7% during the 4th quarter. Mystic Asset Management Inc. now owns 1,267 shares of the medical research company’s stock valued at $330,000 after buying an additional 546 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 0.9 %

Shares of NASDAQ:AMGN opened at $315.75 on Thursday. The firm has a fifty day moving average of $295.15 and a two-hundred day moving average of $299.03. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a market capitalization of $169.62 billion, a P/E ratio of 41.82, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.02%. Amgen’s dividend payout ratio is currently 126.09%.

Insider Activity at Amgen

In other news, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the transaction, the executive vice president now owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. This represents a 16.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Truist Financial reduced their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research note on Wednesday, January 8th. Bank of America upped their target price on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Leerink Partners lowered their price target on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $314.04.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.